We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 50.00 | 2.70% | 1,904.00 | 1,903.00 | 1,905.00 | 1,909.00 | 1,861.00 | 1,861.00 | 140,498 | 13:08:43 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 21.97 | 4.22B |
From Apr 2019 to Apr 2024
TIDMHIK
RNS Number : 1909I
Hikma Pharmaceuticals Plc
19 March 2018
Hikma Pharmaceuticals PLC - EIP Awards
LONDON, 19 March 2018: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 17 March 2016 under the 2014 Executive Incentive Plan ("EIP") which was completed on 19 March 2018. These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the EIP is GBPnil.
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
Hot Features
Premium
1 Details of the person discharging managerial
responsibilities / person closely associated
--- -----------------------------------------------------------
a) Name Said Darwazah
--- --------------------- ------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------
a) Position/status Executive Chairman
--- --------------------- ------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- ------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- -----------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- ------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- ------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- -----------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- ------------------------------------
b) Nature of Shares acquired from vesting of the
the transaction conditional awards on
19 March 2018 under the 2014 EIP.
--- --------------------- ------------------------------------
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 68,346
--- --------------------- ------------------------------------
d) Aggregated N/A
information
--- --------------------- ------------------------------------
e) Date of the 19 March 2018
transaction
--- --------------------- ------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- ------------------------------------
Mazen Darwazah
1 Details of the person discharging managerial
responsibilities / person closely associated
--- -----------------------------------------------------------
a) Name Mazen Darwazah
--- --------------------- ------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------
a) Position/status Executive Vice Chairman
--- --------------------- ------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- ------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- -----------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- ------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- ------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- -----------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- ------------------------------------
b) Nature of Shares acquired from vesting of the
the transaction conditional awards on
19 March 2018 under the 2014 EIP.
--- --------------------- ------------------------------------
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 38,501
--- --------------------- ------------------------------------
d) Aggregated N/A
information
--- --------------------- ------------------------------------
e) Date of the 19 March 2018
transaction
--- --------------------- ------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- ------------------------------------
Bassam Kanaan
1 Details of the person discharging managerial
responsibilities / person closely associated
--- -----------------------------------------------------------
a) Name Bassam Kanaan
--- --------------------- ------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------
a) Position/status PDMR
--- --------------------- ------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- ------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- -----------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- ------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- ------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- -----------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- ------------------------------------
b) Nature of Shares acquired from vesting of the
the transaction conditional awards on
19 March 2018 under the 2014 EIP.
--- --------------------- ------------------------------------
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 26,090
--- --------------------- ------------------------------------
d) Aggregated N/A
information
--- --------------------- ------------------------------------
e) Date of the 19 March 2018
transaction
--- --------------------- ------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- ------------------------------------
Khalid Nabilsi
1 Details of the person discharging managerial
responsibilities / person closely associated
--- -----------------------------------------------------------
a) Name Khalid Nabilsi
--- --------------------- ------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------
a) Position/status PDMR
--- --------------------- ------------------------------------
b) Initial notification Initial notification
/Amendment
--- --------------------- ------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- -----------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- --------------------- ------------------------------------
b) LEI 549300BNS685UXH4JI75
--- --------------------- ------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- -----------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
--- --------------------- ------------------------------------
b) Nature of Shares acquired from vesting of the
the transaction conditional awards on
19 March 2018 under the 2014 EIP.
--- --------------------- ------------------------------------
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 20,400
--- --------------------- ------------------------------------
d) Aggregated N/A
information
--- --------------------- ------------------------------------
e) Date of the 19 March 2018
transaction
--- --------------------- ------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- --------------------- ------------------------------------
Majda Labadi
1 Details of the person discharging managerial
responsibilities / person closely associated
---------------------------------------------------------
a) Name Majda Labadi
-------------------- -----------------------------------
2 Reason for the notification
---------------------------------------------------------
a) Position/status PDMR
-------------------- -----------------------------------
b) Initial notification Initial notification
/Amendment
-------------------- -----------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
---------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
-------------------- -----------------------------------
b) LEI 549300BNS685UXH4JI75
-------------------- -----------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
---------------------------------------------------------
a) Description Description: Ordinary shares of 10
of the financial pence each (Shares)
instrument, ID Code: GB00B0LCW083
type of instrument
and identification
code
-------------------- -----------------------------------
b) Nature of Shares acquired from vesting of the
the transaction conditional awards on
19 March 2018 under the 2014 EIP.
-------------------- -----------------------------------
c) Price(s) and Price(s): GBPnil
volume(s) Volume(s): 14,530
-------------------- -----------------------------------
d) Aggregated N/A
information
-------------------- -----------------------------------
e) Date of the 19 March 2018
transaction
-------------------- -----------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
-------------------- -----------------------------------
Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBUGDXCSBBGIC
(END) Dow Jones Newswires
March 19, 2018 11:50 ET (15:50 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
